Table 1 The antimicrobial susceptibility pattern of blaCTX-M variants in 95 ESBLs producing E. coli.
Antimicrobial drug group | Antimicrobial drug | Percentage | |||
|---|---|---|---|---|---|
blaCTX-M-14 (N = 14) | blaCTX-M-15 (N = 48) | blaCTX-M-27 (N = 16) | blaCTX-M-55 (N = 17) | ||
Penicillins | Ampicillin | 100 | 97.9 | 94.1 | 100 |
Cephalosporins | Ceftazidime | 7.1 | 72.9 | 41.2 | 87.5 |
Cefotaxime | 100 | 100 | 100 | 100 | |
Cefdinir | 100 | 100 | 100 | 100 | |
Ceftriaxone | 85.7 | 97.9 | 94.1 | 100 | |
Cefepime | 57.1 | 91.7 | 41.2 | 93.8 | |
Carbapenems | Doripenem | 0 | 0 | 0 | 0 |
Ertapenem | 0 | 0 | 0 | 0 | |
Imipenem | 0 | 0 | 0 | 0 | |
Meropenem | 0 | 0 | 0 | 0 | |
Fluoroquinolones | Ciprofloxacin | 78.6 | 93.8 | 94.1 | 68.8 |
Levofloxacin | 71.4 | 93.8 | 94.1 | 68.8 | |
Aminoglycoside | Amikacin | 0 | 2.1 | 0 | 0 |
Gentamicin | 35.7 | 68.8 | 29.4 | 75 | |
Combination drugs | Amoxicillin/Clavulanic acid | 50 | 54.2 | 17.6 | 37.5 |
Piperacilin/tazobactam | 7.1 | 4.2 | 0 | 0 | |
